At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
Maimónides Biomedical Research Institute of Córdoba·interventional·Posted Apr 15, 2016·Updated Aug 1, 2017
In Brief
A Phase 2 clinical trial evaluating Paclitaxel and Radical surgery-peritonectomy for Peritoneal Carcinomatosis. Completed, enrolled 32 participants.
Detailed Summary
A randomized controlled single-blind clinical trial was performed, in 32 patients diagnosed with peritoneal carcinomatosis from epithelial ovarian cancer, who underwent radical surgery-peritonectomy, achieving an optimal R0-R1 cytoreduction (microscopic tumor residues (R0) or macroscopic tumor residues \< 1cm (R1)) followed by hyperthermia against normothermia intraperitoneal intraoperative chemotherapy with paclitaxel
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Carcinomatosis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
Primary CompletionNov 2014
First PostedApr 2016
Study CompletionMar 2017
TodayJul 2026
First PostedApr 15, 2016
Enrollment StartJul 1, 2012
Primary CompletionNov 1, 2014
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.2 years ago
Interventions
Paclitaxeldrug
Radical surgery-peritonectomyprocedure